Lyramid has the exclusive worldwide licence to commercialise up to 37 patents related to Midkine-based therapies for the treatment of COVID-19 patients, cancer, autoimmune disorders and chronic kidney disease ("Midkine-Based Therapies")
- Forums
- ASX - By Stock
- AN1
- Roquefort Investments
Roquefort Investments, page-2
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AN1 (ASX) to my watchlist
|
|||||
Last
0.8¢ |
Change
0.001(14.3%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.8¢ | 0.8¢ | 0.8¢ | $11.01K | 1.376M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 123437 | 0.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.9¢ | 80000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 123437 | 0.008 |
1 | 1091271 | 0.007 |
3 | 565639 | 0.006 |
1 | 300000 | 0.005 |
3 | 825000 | 0.004 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 80000 | 1 |
0.010 | 157763 | 1 |
0.013 | 750000 | 1 |
0.015 | 340000 | 2 |
0.016 | 100000 | 1 |
Last trade - 12.36pm 23/08/2024 (20 minute delay) ? |
AN1 (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online